辛巴斯塔丁可以竞争性地抑制脂结合抗脂抗体的细胞信号传递
Dominika Marova1, Paul Frankenbach1, Anne Hollerbach1
1Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Journal of thrombosis and haemostasis : JTH
|September 12, 2025
概括
类药物通过阻止抗脂抗体 (aPLs) 激活单细胞并触发血液凝固来预防抗脂综合征 (APS). 这是由于他类药物干扰了aPL与单细胞上的EPCR/LBPA复合体的结合.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管研究研究心血管研究
- 药理学 药理学 是一个学科.
背景情况:
- 抗脂抗体 (aPLs) 导致抗脂综合征 (APS),导致血栓形成和妊娠并发症.
- 目前正在研究他类药物对管理APS的潜在益处.
研究的目的:
- 研究他类药物对aPL诱导的单细胞激活和组织因子 (TF) 激活的影响.
- 阐明在APS中他类药物的作用背后的细胞机制.
主要方法:
- 单细胞用aPLs和他类药物进行治疗.
- 使用RT-qPCR量化了TF和TNFαmRNA的表达.
- 通过凝血试验测量TF活性.
- 使用显微镜和流细胞计评估了aPL的结合和内部化.
主要成果:
- 西姆瓦斯塔丁抑制了aPLs的TNFα和TF mRNA诱导.
- 类药物阻止了aPL诱导的TF在单细胞表面上的激活.
- 立方体效应独立于HMG-CoA减少酶抑制.
- 类药物从EPCR中取代了LBPA,防止了aPL的结合和下游效应.
结论:
- 类药物抑制了APS中单细胞激活和TF触发的凝血.
- 这是由于他类药物破坏了aPL与单细胞上的EPCR/LBPA复合体的结合.
- 这些发现支持了在APS患者中观察到的他类药物的临床益处.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


